about
Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cellsOccupational Exposure and Health Impairments of Formaldehyde on Employees of a Wood IndustryThe clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia.Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts.PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
P2860
Q28384370-0EE76581-A2ED-4DC7-AB96-A2019FC7B0CBQ28388426-CFA854A6-E2FF-4FDE-B91D-4C2433C3A09CQ33387037-734D8861-FA8B-4D8E-9FF1-9D5FAF370483Q33402882-D64CBF66-066B-42BD-942E-8BE934DA1EE9Q33404600-4DADDEAF-6969-4CCA-8390-9D3A836F7B41Q34273735-BA6E4688-DECF-455D-9C1B-DD2116AC7048Q37669767-1248DB27-AF1E-4E95-BA9B-6F35689A2FA1Q37864686-5BC1B2F2-FC13-4275-A189-740239CF6156Q38047020-FD568A76-CAFA-4FA6-AFFE-957E1A343556Q38507121-C9365B72-EB1C-4561-BBA7-3A08342AF383Q38737783-25876A6D-BCB5-471D-A912-488EF760BFE1Q43195073-70E9D6F5-E8E0-4D88-B0C5-E40288E32109Q48127091-5B2F3FF2-C2DC-44E9-ACE1-BA63538A64A9Q54285466-42DC1B82-35A6-41D8-AB3F-6A8F875B6D66
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myelodysplastic syndromes: biology and treatment.
@en
Myelodysplastic syndromes: biology and treatment.
@nl
type
label
Myelodysplastic syndromes: biology and treatment.
@en
Myelodysplastic syndromes: biology and treatment.
@nl
prefLabel
Myelodysplastic syndromes: biology and treatment.
@en
Myelodysplastic syndromes: biology and treatment.
@nl
P1476
Myelodysplastic syndromes: biology and treatment.
@en
P2093
E Hellström-Lindberg
M Jädersten
P2860
P304
P356
10.1111/J.1365-2796.2008.02052.X
P407
P577
2008-12-17T00:00:00Z